The challenge of immunogenicity in the quest for induced pluripotency

Nature Reviews Immunology

Volumn 10, Issue 12, 2010, Pages 868-875

  Fairchild, Paul J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADULT; BLASTOCYST; CELL NUCLEUS TRANSPLANTATION; CELL THERAPY; CHIMERA; DNA REPAIR; ECTODERM; ENDODERM; HEMATOPOIESIS; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; LEOPARD SYNDROME; LEUKODYSTROPHY; MESODERM; MUTAGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ADULT; ANIMALS; CELL TRANSPLANTATION; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; RATS; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC; TRANSPLANTATION TOLERANCE;

EID: 78649527521     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2878     Document Type: Review

References (84)

1. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
2. Klimanskaya, I., Rosenthal, N. & Lanza, R. Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nature Rev. Drug Discov. 7, 131-142 (2008).
3. Ilic, D. Industry update: latest developments in stem cell research and regenerative medicine. Regen. Med. 4, 607-615 (2009).
4. Wakayama, T. et al. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science 292, 740-743 (2001).
5. Fairchild, P. J., Robertson, N. J., Cartland, S., Nolan, K. F. & Waldmann, H. Cell replacement therapy and the evasion of destructive immunity. Stem Cell Rev. 1, 159-167 (2005).
6. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse fibroblasts and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
7. Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290 (2010).
8. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317 (2007).
9. Zhao, X. et al. iPS cells produce viable mice through tetraploid complementation. Nature 461, 86-90 (2009).
10. Stadtfeld, M. et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465, 175-181 (2010).
11. Stadtfeld, M., Brennand, K. & Hochedlinger, K. Reprogramming of pancreatic β cells into induced pluripotent stem cells. Curr. Biol. 18, 890-894 (2008).
12. Loh, Y.-H. et al. Generation of induced pluripotent stem cells from human blood. Blood 11 3, 5476-5479 (2009).
13. Aoi, T. et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321, 699-702 (2008).
14. Kim, J. B. et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 454, 646-650 (2008).
15. Liao, J. et al. Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 4, 11-15 (2009).
16. Liu, H. et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 3, 587-590 (2008).
17. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
18. Park, I. H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146 (2007).
19. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
20. Nishikawa, S., Goldstein, R. A. & Nierras, C. R. The promise of human induced pluripotent stem cells for research and therapy. Nature Rev. Mol. Cell Biol. 9, 725-729 (2008).
21. Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39-49 (2007).
22. Park, I.-H. et al. Disease-specific induced pluipotent stem cells. Cell 134, 877-886 (2008).
23. Urbach, A., Bar-Nur, O., Daley, G. Q. & Benvenisty, N. Differential modelling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6, 407-411 (2010).
24. Agarwal, S. et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464, 292-296 (2010).
25. Maehr, R. et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc. Natl Acad. Sci. USA 106, 15768-15773 (2009).
26. Dimos, J. T . et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221 (2008).
27. Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280 (2009).
28. Carvajal-Vergara, X. et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812 (2010).
29. Lee, G. et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402-406 (2009).
30. Kazuki, Y. et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol. Ther. 18, 386-393 (2010).
31. Raya, A. et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59 (2009).
32. Wernig, M. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl Acad. Sci. USA 105, 5856-5861 (2008).
33. Xu, D. et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc. Natl Acad. Sci. USA 106, 808-813 (2009).
34. Hanna, J. et al. Treatment of sickle cell anemia mouse model with iPSC generated from autologous skin. Science 318, 1920-1923 (2007).
35. Meng, X.-L. et al. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc. Natl Acad. Sci. USA 107, 7886-7891 (2010).
36. Wang, J. et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nature Biotech. 26, 901-908 (2008).
37. Scandella, D. H. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin. Thromb. Hemost. 26, 137-142 (2000).
38. Kirouac, D. C. & Zandstra, P. W. The systematic production of cells for cell therapies. Cell Stem Cell 3, 369-381 (2008).
39. Nakatsuji, N., Nakajima, F. & Tokunaga, K. HLA-haplotype banking and iPS cells. Nature Biotech. 26, 739-740 (2008).
40. Fairchild, P. J. Transplantation tolerance in an age of induced pluripotency. Curr. Opin. Organ Transplant. 14, 321-325 (2009).
41. Erlich, H. A., Opelz, G. & Hansen, J. HLA DNA typing and transplantation. Immunity 14, 347-356 (2001).
42. Lin, G. et al. HLA-matching potential of an established human embryonic stem cell bank in China. Cell Stem Cell 5, 461-465 (2009).
43. Aasen, T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotech. 26, 1276-1284 (2008).
44. Giorgetti, A. et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5, 353-357 (2009).
45. Gluckman, E. & Rocha, V. Cord blood transplantation: state of the art. Haematologica 94, 451-454 (2009).
46. Robertson, N. J. et al. Embryonic stem cell-derived tissues are immunogenic but their innate immune privilege promotes the induction of tolerance. Proc. Natl Acad. Sci. USA 104, 20920-20925 (2007).
47. Miura, K. et al. Variation in the safety of induced pluripotent stem cell lines. Nature Biotech. 27, 743-745 (2009).
48. Amariglio, N. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029 (2010).
49. Swijnenburg, R. J. et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl Acad. Sci. USA 105, 12991-12996 (2008).
50. Lui, K. O., Boyd, A. S., Cobbold, S. P., Waldmann, H. & Fairchild, P. J. A role for regulatory T cells in acceptance of embryonic stem cell-derived tissues transplanted across an MHC barrier. Stem Cells 28, 1905-1914 (2010).
51. Daley, S. R., Ma, J., Adams, E., Cobbold, S. P. & Waldmann, H. A key role for TGF-β signaling to T cells in the long-term acceptance of allografts. J. Immunol. 179, 3648-3654 (2007).
52. Ildstad, S. T. & Sachs, D. H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307, 168-170 (1984).
53. Sykes, M. Mixed chimerism and transplant tolerance. Immunity 14, 417-424 (2001).
54. Fuchimoto, Y. et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J. Clin. Invest. 105, 1779-1789 (2000).
55. Huang, C. A. et al. Stable mixed chimerism and tolerance using a non-myeloablative preparative regimen in a large animal model. J. Clin. Invest. 105, 173-181 (2000).
56. Kaufman, D. S. & Thomson, J. A. Human ES cells - haematopoiesis and transplantation strategies. J. Anat. 200, 243-248 (2002).
57. Burt, R. K. et al. Embryonic stem cells as an alternative marrow donor source: engraftment without graft-versus-host disease. J. Exp. Med. 199, 895-904 (2004).
58. Verda, L. et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 26, 381-386 (2008).
59. Priddle, H., Jones, D. R., Burridge, P. W. & Patient, R. Hematopoiesis from human embryonic stem cells: overcoming the immune barrier in stem cell therapies. Stem Cells 24, 815-824 (2006).
60. Silk, K. M. & Fairchild, P. J. Harnessing dendritic cells for the induction of transplantation tolerance. Curr. Opin. Organ Transplant. 145, 344-350 (2009).
61. Senju, S. et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 27, 1021-1031 (2009).
62. + progenitors. J. Clin. Invest. 11 9, 2818-2829 (2009).
63. Yates, S. et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J. Immunol. 179, 967-976 (2007).
64. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178, 7018-7031 (2007).
65. Horibe, E. K. et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transplant. Immunol. 18, 307-318 (2008).
66. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
67. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869 (2003).
68. + T cell tolerance through PD-1 and CTLA-4. Nature Immunol. 6, 280-286 (2005).
69. Kakkis, E. et al. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc. Natl Acad. Sci. USA 101, 829-834 (2004).
70. Dickson, P. et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J. Clin. Invest. 11 8, 2868-2876 (2008).
71. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
72. + regulatory T cells in vivo in humans. Blood 100, 174-177 (2002).
73. Stadtfeld, M. et al. Induced pluripotent stem cells generated without viral integration. Science 322, 945-949 (2008).
74. Okita, K. et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322, 949-953 (2008).
75. Kaji, K. et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-775 (2009).
76. Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770 (2009).
77. Ichida, J. K. et al. A small molecule inhibitor of TGF-β signalling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell 5, 491-503 (2009).
78. Maherali, N. & Hochedlinger, K. TGFβ signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr. Biol. 19, 1718-1723 (2009).
79. Feng, B., Ng, J. H., Heng, J. C. D. & Ng, H.-H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 4, 301-312 (2009).
80. Huangfu, D. et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotech. 26, 1269-1275 (2008).
81. Zhou, H. et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4, 381-384 (2009).
82. Kim, D. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472-476 (2009).
83. Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154-156 (1981).
84. Kaufman, D. S., Hanson, E. T., Lewis, R. L., Auerbach, R. & Thomson, J. A. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. USA 98, 10716-10721 (2001).